Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: additional insights

Bibliographic Details
Main Authors:	Patrick M. Honore, Aude Mugisha, Leonel Barreto Gutierrez, Sebastien Redant, Keitiane Kaefer, Andrea Gallerani, David De Bels
Format:	Article
Language:	English
Published:	BMC 2019-12-01
Series:	Critical Care
Online Access:	https://doi.org/10.1186/s13054-019-2692-2

Similar Items

Optimizing ceftolozane-tazobactam dosage during continuous renal replacement therapy: some nuances
by: Gerardo Aguilar, et al.
Published: (2020-01-01)

Biomarker suPAR seems a good prognostic factor for community-acquired pneumonia but less prominent for septic shock
by: Patrick M. Honore, et al.
Published: (2019-12-01)

Dysbiosis of the microbiota in neurocritically ill patients associated with coma and death: ammonia as a potential missing link
by: Patrick M. Honore, et al.
Published: (2019-12-01)

Interleukin-26 is a promising biomarker of sepsis but is it always reliable?
by: Patrick M. Honore, et al.
Published: (2019-12-01)

Optimizing ceftolozane-tazobactam dosage in critically ill patients during continuous venovenous hemodiafiltration
by: Gerardo Aguilar, et al.
Published: (2019-04-01)

What should be the best dialysis catheter lock in critically ill patients?
by: Patrick M. Honore, et al.
Published: (2019-10-01)

Obesity inducing acute respiratory distress syndrome: we should choose the right population!
by: Patrick M. Honore, et al.
Published: (2019-10-01)

How levosimendan can improve renal function?
by: Patrick M. Honore, et al.
Published: (2019-10-01)

Ceftolozane/Tazobactam Dosing Requirements Against Bacteremia
by: Jesus Ruiz, et al.
Published: (2020-01-01)

Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
by: Marco Fiore, et al.
Published: (2021-01-01)

Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa
by: Melissa D. Barnes, et al.
Published: (2018-12-01)

Chemical Stability of Ceftolozane/Tazobactam in Polyvinylchloride Bags and Elastomeric Pumps
by: Joseph Terracciano, PhD, et al.
Published: (2017-01-01)

Ceftolozane/Tazobactam Resistance and Mechanisms in Carbapenem-Nonsusceptible Pseudomonas aeruginosa
by: Jocelyn Qi-Min Teo, et al.
Published: (2021-02-01)

Who may benefit most from future vitamin D intervention trials: do not forget patients on continuous renal replacement therapy
by: Patrick M. Honore, et al.
Published: (2020-04-01)

High levels of plasma biomarkers at 24 h were found to be strong predictors of 90-day mortality: beware of some potential confounders!
by: Patrick M. Honore, et al.
Published: (2021-03-01)

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
by: Kıvanç ŞEREFHANOĞLU
Published: (2019-12-01)

Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
by: Golub A.V., et al.
Published: (2018-11-01)

Monotherapy of ceftazidime–avibactam and ceftolozane–tazobactam against multidrug-resistant organisms
by: Adnan Alatoom
Published: (2017-09-01)

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections
by: Goodlet KJ, et al.
Published: (2016-12-01)

Use of Ceftolozane/Tazobactam in a Case of Septic Shock by Puerperal Sepsis
by: Mario Pezzi, et al.
Published: (2019-01-01)

Real-world use of ceftolozane/tazobactam: a systematic literature review
by: Laura Puzniak, et al.
Published: (2021-04-01)

Experience With Ceftolozane-Tazobactam for the Treatment of Serious Infections in Saudi Tertiary Care Center
by: M Bosaeed, et al.
Published: (2020-02-01)

Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections
by: Skalweit MJ
Published: (2015-06-01)

Treatment of Polymicrobial Osteomyelitis with Ceftolozane-Tazobactam: Case Report and Sensitivity Testing of Isolates
by: Jeffrey C. Jolliff, et al.
Published: (2016-01-01)

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination
by: Hong MC, et al.
Published: (2013-11-01)

Higher incidence of arrhythmia in COVID-19 than in other community-acquired pneumonia: possible role of concurrent therapies
by: Patrick M. Honore, et al.
Published: (2021-07-01)

Success rate of naso-jejunal tube placement influenced by CRRT: possible removal of metoclopramide
by: Patrick M. Honore, et al.
Published: (2021-06-01)

Adsorption and caspofungin dosing during continuous renal replacement therapy
by: Patrick M. Honore, et al.
Published: (2019-07-01)

Ceftolozane–tazobactam for the treatment of osteomyelitis caused by multidrug-resistant pathogens: a case series
by: Xing Tan, et al.
Published: (2019-07-01)

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury
by: Laura Butragueño-Laiseca, et al.
Published: (2020-12-01)

Cost-effectiveness of ceftolozane/tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia
by: Fabián Hernández
Published: (2020-02-01)

Ceftolozane-tazobactam in combination with fosfomycin for treatment of MDR/XDR P. aeruginosa infective endocarditis
by: A. Prescott, et al.
Published: (2019-10-01)

In Vitro Activity of Ceftolozane/tazobactam and Ceftazidime/avibactam Against Carbapenemase-producing Pseudomonas aeruginosa
by: Özlem AYDEMİR, et al.
Published: (2019-12-01)

Influence of extracorporeal membrane oxygenation on the pharmacokinetics of ceftolozane/tazobactam: an ex vivo and in vivo study
by: Camille Mané, et al.
Published: (2020-05-01)

Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
by: Giancola SE, et al.
Published: (2016-05-01)

Treatment of bone and joint infections by ceftazidime/avibactam and ceftolozane/tazobactam: a cohort study
by: Claire Rempenault, et al.
Published: (2021-06-01)

Austrian recommendations for best clinical practice in case of haemorrhagic traumatic brain injury under platelet inhibitors or non-vitamin K antagonist oral anticoagulants: an additional therapeutic option to consider
by: Patrick M. Honore, et al.
Published: (2020-05-01)

Endocan removal during continuous renal replacement therapy: does it affect the reliability of this biomarker?
by: Patrick M. Honore, et al.
Published: (2019-05-01)

Efflux Pump AcrAB Confers Decreased Susceptibility to Piperacillin–Tazobactam and Ceftolozane–Tazobactam in Tigecycline-Non-Susceptible Klebsiella pneumoniae
by: Li J, et al.
Published: (2020-11-01)

The safety of ceftolozane-tazobactam for the treatment of acute bacterial infections: a systemic review and meta-analysis
by: Li-Ting Wang, et al.
Published: (2021-07-01)